Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pseudomyxoma Peritonei 2Pain, Postoperative 1Neoplasms, Cystic, Mucinous, and Serous 1Neoplasms 1Breast Neoplasms 1Adenocarcinoma, Mucinous 1

Interventions

atezolizumab 2Paclitaxel 2Nivolumab 2Immunoglobulin G 2Disulfides 2Bevacizumab 2irinotecan sucrosofate 1cobimetinib 1Taxes 1Specimen Handling 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Gemcitabine 1Fluorouracil 1Famotidine 1Docetaxel 1Diphenhydramine 1Dexamethasone 1Chemoradiotherapy 1Carboplatin 1Calcium Dobesilate 1CTLA-4 Antigen 1Bromelains 1Axitinib 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma, Mucinous × Bromelains × Clear all
NCT03976973 2022-03-15

BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

Mucpharm Pty Ltd

Phase 2 Unknown
62 enrolled

Adenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Neoplasms, Cystic, Mucinous, and Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡